Novel Grb14-mediated cross talk between insulin and p62/Nrf2 pathways regulates liver lipogenesis and selective insulin resistance

Molecular and Cellular Biology

Volumn 36, Issue 15, 2016, Pages 2168-2181

  Popineau, Lucie ^a,b,c   Morzyglod, Lucille ^a,b,c   Carré, Nadége ^a,b,c   Caüzac, Michèle ^a,b,c   Bossard, Pascale ^a,b,c   Prip Buus, Carina ^a,b,c   Lenoir, Véronique ^a,b,c   Ragazzon, Bruno ^a,b,c   Robert, Véronique ^a,b,c   Robert, Lorenne ^d,e,f   Guilmeau, Sandra ^a,b,c   Postic, Catherine ^a,b,c   Komatsu, Masaaki ^g   Canonne Hergaux, François ^d,e,f   Burnol, Hervé ^h,i   Burnol, Anne Françoise ^a,b,c  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSERM   (France)

^e University of Toulouse III   (France)

^f UMR 1220 TCEM (INRA ENITAB)   (France)

^g TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^h CEMAGREF   (France)

ⁱ TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; GLUCOSE; GROWTH FACTOR RECEPTOR BINDING PROTEIN 14; INSULIN; LIVER X RECEPTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GRB14 PROTEIN, MOUSE; INSULIN RECEPTOR; NFE2L2 PROTEIN, MOUSE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID SYNTHESIS; FATTY LIVER; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CYTOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LIVER; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; INSULIN RESISTANCE; LIPOGENESIS; LIVER; LIVER X RECEPTORS; MICE; NF-E2-RELATED FACTOR 2; PROTEINS; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84982798375     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00170-16     Document Type: Article

References (58)

1. Brown MS, Goldstein JL. 2008. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95-96. http://dx.doi.org/10.1016/j.cmet.2007.12.009.
2. Taniguchi CM, Emanuelli B, Kahn CR. 2006. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85-96.
3. Smith BW, Adams LA. 2011. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 7:456-465. http://dx.doi.org/10.1038/nrendo.2011.72.
4. Jeon TI, Osborne TF. 2012. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab 23:65-72. http://dx.doi.org/10.1016/j.tem.2011.10.004.
5. Kasus-Jacobi A, Perdereau D, Auzan C, Clauser E, Van Obberghen E, Mauvais-Jarvis F, Girard J, Burnol A-F. 1998. Identification of the rat adapter Grb14 as an inhibitor of insulin actions. J Biol Chem 273:26026-26035. http://dx.doi.org/10.1074/jbc.273.40.26026.
6. Kooner JS, Saleheen D, Sim X, Sehmi J, Zhang W, Frossard P, Been LF, Chia KS, Dimas AS, Hassanali N, Jafar T, Jowett JB, Li X, Radha V, Rees SD, Takeuchi F, Young R, Aung T, Basit A, Chidambaram M, Das D, Grundberg E, Hedman AK, Hydrie ZI, Islam M, Khor CC, Kowlessur S, Kristensen MM, Liju S, Lim WY, Matthews DR, Liu J, Morris AP, Nica AC, Pinidiyapathirage JM, Prokopenko I, Rasheed A, Samuel M, Shah N, Shera AS, Small KS, Suo C, Wickremasinghe AR, Wong TY, Yang M, Zhang F, Abecasis GR, Barnett AH, Caulfield M, Deloukas P, Frayling TM, Froguel P, Kato N, Katulanda P, Kelly MA, Liang J, Mohan V, Sanghera DK, Scott J, Seielstad M, Zimmet PZ, Elliott P, Teo YY, McCarthy MI, Danesh J, Tai ES, Chambers JC. 2011. Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat Genet 43:984-989. http://dx.doi.org/10.1038/ng.921.
7. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, Rybin D, Liu CT, Bielak LF, Prokopenko I, Amin N, Barnes D, Cadby G, Hottenga JJ, Ingelsson E, Jackson AU, Johnson T, Kanoni S, Ladenvall C, Lagou V, Lahti J, Lecoeur C, Liu Y, Martinez-Larrad MT, Montasser ME, Navarro P, Perry JR, Rasmussen-Torvik LJ, Salo P, Sattar N, Shungin D, Strawbridge RJ, Tanaka T, van Duijn CM, An P, de Andrade M, Andrews JS, Aspelund T, Atalay M, Aulchenko Y, Balkau B, Bandinelli S, Beckmann JS, Beilby JP, Bellis C, Bergman RN, Blangero J, Boban M, Boehnke M, Boerwinkle E, et al. 2012. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet 44: 659-669. http://dx.doi.org/10.1038/ng.2274.
8. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, Strawbridge RJ, Khan H, Grallert H, Mahajan A, Prokopenko I, Kang HM, Dina C, Esko T, Fraser RM, Kanoni S, Kumar A, Lagou V, Langenberg C, Luan J, Lindgren CM, Muller-Nurasyid M, Pechlivanis S, Rayner NW, Scott LJ, Wiltshire S, Yengo L, Kinnunen L, Rossin EJ, Raychaudhuri S, Johnson AD, Dimas AS, Loos RJ, Vedantam S, Chen H, Florez JC, Fox C, Liu CT, Rybin D, Couper DJ, Kao WH, Li M, Cornelis MC, Kraft P, Sun Q, van Dam RM, Stringham HM, Chines PS, Fischer K, Fontanillas P, et al. 2012. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 44:981-990. http://dx.doi.org/10.1038/ng.2383.
9. Cariou B, Capitaine N, Le Marcis V, Vega N, Bereziat V, Kergoat M, Laville M, Girard J, Vidal H, Burnol AF. 2004. Increased adipose tissue expression of Grb14 in several models of insulin resistance. FASEB J 18: 965-967.
10. Park JJ, Berggren JR, Hulver MW, Houmard JA, Hoffman EP. 2006. GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiol Genomics 27:114-121. http://dx.doi.org/10.1152/physiolgenomics.00045.2006.
11. Bereziat V, Kasus-Jacobi A, Perdereau D, Cariou B, Girard J, Burnol A-F. 2002. Inhibition of insulin receptor catalytic activity by the molecular adapter Grb14. J Biol Chem 277:4845-4852. http://dx.doi.org/10.1074/jbc.M106574200.
12. Desbuquois B, Bereziat V, Authier F, Girard J, Burnol AF. 2008. Compartmentalization and in vivo insulin-induced translocation of the insulin-signaling inhibitor Grb14 in rat liver. FEBS J 275:4363-4377. http://dx.doi.org/10.1111/j.1742-4658.2008.06583.x.
13. Carré N, Caüzac M, Girard J, Burnol A-F. 2008. Dual effect of the adapter Grb14 on insulin action in primary hepatocytes. Endocrinology 149:3109-3117. http://dx.doi.org/10.1210/en.2007-1196.
14. Goenaga D, Hampe C, Carre N, Cailliau K, Browaeys-Poly E, Perdereau D, Holt LJ, Daly RJ, Girard J, Broutin I, Issad T, Burnol AF. 2009. Molecular determinants of Grb14-mediated inhibition of insulin signaling. Mol Endocrinol 23:1043-1051. http://dx.doi.org/10.1210/me.2008-0360.
15. Cariou B, Perdereau D, Cailliau K, Browaeys-Poly E, Béréziat V, Vasseur-Cognet M, Girard J, Burnol A-F. 2002. The adapter protein ZIP binds Grb14 and regulates its inhibitory action on insulin signaling by recruiting protein kinase Cz. Mol Cell Biol 22:6959-6970. http://dx.doi.org/10.1128/MCB.22.20.6959-6970.2002.
16. Moscat J, Diaz-Meco MT. 2012. p62: a versatile multitasker takes on cancer. Trends Biochem Sci 37:230-236. http://dx.doi.org/10.1016/j.tibs.2012.02.008.
17. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y. 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313-322. http://dx.doi.org/10.1006/bbrc.1997.6943.
18. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. 2007. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 28:91-106. http://dx.doi.org/10.1016/j.molcel.2007.07.032.
19. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C. 2006. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 55:2159-2170. http://dx.doi.org/10.2337/db06-0200.
20. Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, Hoshii T, Hirao A, Takagi K, Mizushima T, Motohashi H, Lee MS, Yoshimori T, Tanaka K, Yamamoto M, Komatsu M. 2013. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 51:618-631. http://dx.doi.org/10.1016/j.molcel.2013.08.003.
21. Wang XJ, Hayes JD, Wolf CR. 2006. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res 66:10983-10994. http://dx.doi.org/10.1158/0008-5472.CAN-06-2298.
22. Stansbie D, Brownsey RW, Crettaz M, Denton RM. 1976. Acute effects in vivo of anti-insulin serum on rates of fatty acid synthesis and activities of acetyl-coenzyme A carboxylase and pyruvate dehydrogenase in liver and epididymal adipose tissue of fed rats. Biochem J 160:413-416. http://dx.doi.org/10.1042/bj1600413.
23. Bobard A, Hainault I, Ferre P, Foufelle F, Bossard P. 2005. Differential regulation of sterol regulatory element-binding protein 1c transcriptional activity by insulin and liver X receptor during liver development. J Biol Chem 280:199-206. http://dx.doi.org/10.1074/jbc.M406522200.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545-15550. http://dx.doi.org/10.1073/pnas.0506580102.
25. Ducheix S, Podechard N, Lasserre F, Polizzi A, Pommier A, Murzilli S, Di Lisio C, D'Amore S, Bertrand-Michel J, Montagner A, Pineau T, Loiseau N, Lobaccaro JM, Martin PG, Guillou H. 2013. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARalpha. Biochimie 95:556-567. http://dx.doi.org/10.1016/j.biochi.2012.09.028.
26. Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, Liby KT, Sporn MB, Sutter TR, Kensler TW. 2009. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 30:1024-1031. http://dx.doi.org/10.1093/carcin/bgp100.
27. Hegarty BD, Bobard A, Hainault I, Ferre P, Bossard P, Foufelle F. 2005. Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c. Proc Natl Acad SciUSA 102:791-796. http://dx.doi.org/10.1073/pnas.0405067102.
28. Goldstein JL, DeBose-Boyd RA, Brown MS. 2006. Protein sensors for membrane sterols. Cell 124:35-46. http://dx.doi.org/10.1016/j.cell.2005.12.022.
29. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. 2004. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 101:11245-11250. http://dx.doi.org/10.1073/pnas.0404297101.
30. Kay HY, Kim WD, Hwang SJ, Choi HS, Gilroy RK, Wan YJ, Kim SG. 2011. Nrf2 inhibits LXRalpha-dependent hepatic lipogenesis by competing with FXR for acetylase binding. Antioxid Redox Signal 15:2135-2146. http://dx.doi.org/10.1089/ars.2010.3834.
31. Steffensen KR, Jakobsson T, Gustafsson JA. 2013. Targeting liver X receptors in inflammation. Expert Opin Ther Targets 17:977-990. http://dx.doi.org/10.1517/14728222.2013.806490.
32. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, Yamamoto M. 2010. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12:213-223. http://dx.doi.org/10.1038/ncb2021.
33. Bryan HK, Olayanju A, Goldring CE, Park BK. 2013. The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation. Biochem Pharmacol 85:705-717. http://dx.doi.org/10.1016/j.bcp.2012.11.016.
34. Komatsu M. 2012. Liver autophagy: physiology and pathology. J Biochem 152:5-15. http://dx.doi.org/10.1093/jb/mvs059.
35. Rabinowitz JD, White E. 2010. Autophagy and metabolism. Science 330:1344-1348. http://dx.doi.org/10.1126/science.1193497.
36. Depetris RS, Hu J, Gimpelevich I, Holt LJ, Daly RJ, Hubbard SR. 2005. Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14. Mol Cell 20:325-333. http://dx.doi.org/10.1016/j.molcel.2005.09.001.
37. Cooney GJ, Lyons RJ, Crew AJ, Jensen TE, Molero JC, Mitchell CJ, Biden TJ, Ormandy CJ, James DE, Daly RJ. 2004. Improved glucose homeostasis and enhanced insulin signalling in Grb14-deficient mice. EMBO J 23:582-593. http://dx.doi.org/10.1038/sj.emboj.7600082.
38. Calkin AC, Tontonoz P. 2012. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 13:213-224. http://dx.doi.org/10.1038/nrm3312.
39. Jakobsson T, Treuter E, Gustafsson JA, Steffensen KR. 2012. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol Sci 33:394-404. http://dx.doi.org/10.1016/j.tips.2012.03.013.
40. Hong C, Tontonoz P. 2014. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov 13:433-444. http://dx.doi.org/10.1038/nrd4280.
41. Zhang Y, Breevoort SR, Angdisen J, Fu M, Schmidt DR, Holmstrom SR, Kliewer SA, Mangelsdorf DJ, Schulman IG. 2012. Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest 122:1688-1699. http://dx.doi.org/10.1172/JC159817.
42. Baird L, Dinkova-Kostova AT. 2011. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 85:241-272. http://dx.doi.org/10.1007/s00204-011-0674-5.
43. Kitteringham NR, Abdullah A, Walsh J, Randle L, Jenkins RE, Sison R, Goldring CE, Powell H, Sanderson C, Williams S, Higgins L, Yamamoto M, Hayes J, Park BK. 2010. Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. J Proteomics 73:1612-1631. http://dx.doi.org/10.1016/j.jprot.2010.03.018.
44. Tanaka Y, Aleksunes LM, Yeager RL, Gyamfi MA, Esterly N, Guo GL, Klaassen CD. 2008. NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. J Pharmacol Exp Ther 325:655-664. http://dx.doi.org/10.1124/jpet.107.135822.
45. Hwahng SH, Ki SH, Bae EJ, Kim HE, Kim SG. 2009. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 49:1913-1925. http://dx.doi.org/10.1002/hep.22887.
46. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. 2004. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113:1408-1418. http://dx.doi.org/10.1172/JC121025.
47. Uruno A, Furusawa Y, Yagishita Y, Fukutomi T, Muramatsu H, Negishi T, Sugawara A, Kensler TW, Yamamoto M. 2013. The Keap1-Nrf2 system prevents onset of diabetes mellitus. Mol Cell Biol 33:2996-3010. http://dx.doi.org/10.1128/MCB.00225-13.
48. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H. 2012. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22:66-79. http://dx.doi.org/10.1016/j.ccr.2012.05.016.
49. Jain A, Lamark T, Sjottem E, Larsen KB, Awuh JA, Overvatn A, McMahon M, Hayes JD, Johansen T. 2010. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 285:22576-22591. http://dx.doi.org/10.1074/jbc.M110.118976.
50. Duran A, Amanchy R, Linares JF, Joshi J, Abu-Baker S, Porollo A, Hansen M, Moscat J, Diaz-Meco MT. 2011. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol Cell 44:134-146. http://dx.doi.org/10.1016/j.molcel.2011.06.038.
51. Li S, Brown MS, Goldstein JL. 2010. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 107:3441-3446. http://dx.doi.org/10.1073/pnas.0914798107.
52. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, Gorgun C, Kwiatkowski DJ, Hotamisligil GS, Lee CH, Manning BD. 2011. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 14:21-32. http://dx.doi.org/10.1016/j.cmet.2011.06.002.
53. Loh K, Deng H, Fukushima A, Cai X, Boivin B, Galic S, Bruce C, Shields BJ, Skiba B, Ooms LM, Stepto N, Wu B, Mitchell CA, Tonks NK, Watt MJ, Febbraio MA, Crack PJ, Andrikopoulos S, Tiganis T. 2009. Reactive oxygen species enhance insulin sensitivity. Cell Metab 10: 260-272. http://dx.doi.org/10.1016/j.cmet.2009.08.009.
54. Tiganis T. 2011. Reactive oxygen species and insulin resistance: the good, the bad and the ugly. Trends Pharmacol Sci 32:82-89. http://dx.doi.org/10.1016/j.tips.2010.11.006.
55. Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. 2010. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 38:2293-2301. http://dx.doi.org/10.1124/dmd.110.035006.
56. Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML, Hayes JD. 2010. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 48:357-371. http://dx.doi.org/10.1016/j.freeradbiomed.2009.11.007.
57. Meakin PJ, Chowdhry S, Sharma RS, Ashford FB, Walsh SV, McCrimmon RJ, Dinkova-Kostova AT, Dillon JF, Hayes JD, Ashford ML. 2014. Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol 34:3305-3320. http://dx.doi.org/10.1128/MCB.00677-14.
58. Uruno A, Yagishita Y, Yamamoto M. 2015. The Keap1-Nrf2 system and diabetes mellitus. Arch Biochem Biophys 566:76-84. http://dx.doi.org/10.1016/j.abb.2014.12.012.